HOME >> MEDICINE >> NEWS
Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease

FREMONT, Calif., May 18, 1999 -- Abgenix, Inc. (Nasdaq: ABGX) reported today additional results of a Phase II clinical trial of ABX-CBL in graft versus host disease ("GVHD"). ABX-CBL is a proprietary in-licensed mouse antibody that binds to the CBL antigen. The CBL antigen is upregulated on activated immune cells, including T cells, B cells and natural killer cells. The completed trial involved patients in four dose cohorts with severe GVHD, an often fatal side effect of bone marrow transplants ("BMT"). Among patients in the three higher dose cohorts, 56% (10 of 18) survived at least 100 days from the start of treatment with ABX-CBL. This compared favorably to a 22% (2 of 9) survival rate in the low dose cohort. Robert Rivkin, M.D. of the Rocky Mountain Cancer Centers in Denver, Colorado, presented the details of the clinical trial today at the 1999 Annual Meeting of the American Society of Clinical Oncology.

"We believe the survival data reported today strengthens the preliminary safety and response rate data reported earlier," stated R. Scott Greer, president and chief executive officer of Abgenix. "We plan to initiate a pivotal Phase III clinical trial for ABX-CBL as soon as feasible after we have approval from the FDA to proceed."

In March, at the International Bone Marrow Transplant Registry ("IBMTR") meeting, it was reported that, among patients in the three higher dose cohorts, 73% (11 of 15) had a two grade or better improvement in the IBMTR GVHD Severity Scale. This compared favorably to a 25% (2 of 8) response rate in the low dose cohort.

GHVD is a life threatening complication that frequently occurs following an allogeneic BMT. BMTs are used in the treatment of patients with end stage leukemia, certain other serious cancers and immune system disorders. An allogeneic BMT procedure involves transferring marrow, the graft, from a healthy person into an immunosuppressed patient, the host. The transplant is intended to restore nor
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
18-May-1999


Page: 1 2

Related medicine news :

1. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
2. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
3. UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer
4. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
5. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
6. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
7. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
8. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
9. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
10. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports
11. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/2/2018)... (PRWEB) , ... September 01, ... ... Mammography is proud to add HydraFacial MD® Elite to its leading menu ... uses patented, vortex-suction technology and an infusion of clinically-proven ingredients to dramatically ...
(Date:9/1/2018)... ... August 31, 2018 , ... SignatureCare Emergency Center is ... for the Fall semester to a deserving student. Get your applications in now as ... was awarded to Hanna Wu who is a medical student at Texas Southern University. ...
(Date:8/31/2018)... , ... August 31, 2018 , ... ... | 2018" list. , This list includes independent community hospitals as well as ... others care for small communities outside of large cities. The hospitals continue to ...
(Date:8/31/2018)... ... 31, 2018 , ... The social impact documentary feature film on homelessness, OFF ... NIH-funded researcher Luciana Lagana, aka Dr. Luciana, has been faring well at film ... Film Festival, IndieFEST Film Awards, Shawna Shea Memorial Film Festival, and Top Indie Film ...
(Date:8/31/2018)... ... August 31, 2018 , ... Rudina Thanasi, a scientifically validated ... energy treated nutraceutical to improve overall immunity and to combat inflammatory and autoimmune ... well as, inflammation. The following data was reported:,     Over ...
Breaking Medicine News(10 mins):
(Date:9/15/2018)... Calif. (PRWEB) , ... September ... ... phage display for molecular evolution incorporate deep sequencing to enable greater library ... construction and biophysical follow-up of potential hits remain. , Multiplexed phage display ...
(Date:9/13/2018)... (PRWEB) , ... September 13, 2018 , ... The ultimate ... Located at 31-57 31st St., the new arrival is called Form50 Fitness . ... by Sebastien Lagree called The Megaformer™ - a hybrid Pilates reformer with pulleys, weights, ...
(Date:9/13/2018)... ... September 13, 2018 , ... NCPDP announced today that its ... correct implementation of the NCPDP SCRIPT Standard Version 2017071 ahead of the January ... identified by the industry as vital enhancements in improving patient safety, clinical decision-making, ...
Breaking Medicine Technology:
Cached News: